A Phase I Trial to Investigate the Tolerability, Safety, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Japanese Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion Part in Asian Subjects With Gastric Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Avelumab (Primary)
- Indications Gastric cancer; Solid tumours
- Focus Adverse reactions
- Acronyms JAVELIN Solid Tumor Japan
- Sponsors Merck KGaA; Merck Serono
- 19 Jun 2017 Planned End Date changed from 1 May 2017 to 28 Dec 2018.
- 24 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 May 2017 as reported by ClinicalTrials.gov.
- 24 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.